Hope for those suffering from high blood pressure may be on the way, thanks to an international clinical trial whose sole Connecticut participant is Stamford Health.
The ongoing multicenter Radiance-HTN study is being conducted at 21 centers in the U.S. and 18 in Europe. The aim is to evaluate whether an investigational medical device manufactured by ReCor Medical of Palo Alto, Calif. and the U.K. called the Paradise Renal Denervation System can lower high blood pressure, or hypertension, in patients known to have mild to moderate levels of the condition.
In some patients with high blood pressure, the nerves surrounding the blood vessels leading to the kidneys — renal arteries — are too active, which may cause high blood pressure. The minimally invasive procedure behind the RADIANCE-HTN trial involves the delivery of ultrasound energy to control blood pressure and treat hyperactive renal nerves. A small catheter is inserted into the renal artery and ultrasound energy (heat) is delivered through the tissue surrounding the artery to interrupt the signaling of the renal nerves.
By treating the nerves that run to the kidney, blood pressure may decrease. After both kidneys are treated, the catheter is removed, leaving nothing behind.
“We are excited to be a part of this important study that is not only advancing our knowledge about treatment for hypertension, but also allows certain patients the ability to potentially take fewer or no hypertension medications,” said Dr. David Hsi, chief of cardiology and co-director of the Stamford Health Heart and Vascular Institute, who is serving as its principal investigator of the RADIANCE-HTN trial, in a statement.